You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Porcupine inhibitor

Showing 26 - 50 of 7,356
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hidradenitis Suppurativa Trial in Tampa, Baton Rouge (Placebo, Izokibep)

Recruiting
  • Hidradenitis Suppurativa
  • Tampa, Florida
  • +1 more
Jun 20, 2023

Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

Recruiting
  • Toxic Epidermal Necrolysis
  • Fuzhou, Fujian, China
    Department of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)

Recruiting
  • Tumor, Solid
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 30, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in United States (VS-6766 and sotorasib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766) and sotorasib
  • Washington, District of Columbia
  • +6 more
Jan 31, 2023

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Determine Pro-Inflammatory Cytokine Kinetics During Immune

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Melanoma
    • Indianapolis, Indiana
      Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
    Jan 30, 2023

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)

    Active, not recruiting
    • Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • Paris, France
    • +6 more
    Dec 15, 2022

    NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Yuma, Arizona
    • +178 more
    Dec 19, 2022

    Depressive Disorder, Major Trial in Worldwide (Esketamine, SSRI/SNRI)

    Active, not recruiting
    • Depressive Disorder, Major
    • Ciudad Autonoma de Buenos Aires, Argentina
    • +58 more
    Jan 31, 2023

    Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

    Active, not recruiting
    • Breast Cancer
    • Guangzhou, Guangdong, China
      State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
    Jan 27, 2023

    Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

    Not yet recruiting
    • Advanced Lung Squamous Cell Carcinoma
    • low-dose radiation therapy and stereotactic body radiation therapy
    • +2 more
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Nov 13, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Radiotherapy
    • +4 more
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Sep 14, 2023

    Migraine, Episodic Migraine, Headache Trial in New York (Click Digital Therapeutic)

    Recruiting
    • Migraine
    • +3 more
    • Click Digital Therapeutic
    • New York, New York
      Click Therapeutics
    Aug 15, 2023

    NSCLC Trial in Worldwide (JTX-4014, Vopratelimab)

    Active, not recruiting
    • NSCLC
    • Minsk, Belarus
    • +70 more
    Jan 18, 2023

    Hypertension Trial in Burke (lorundrostat, Placebo)

    Recruiting
    • Hypertension
    • Burke, Virginia
      Burke Internal Medicine
    Aug 2, 2023

    Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma Trial in United States (Abemaciclib, Tamoxifen,

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Boston, Massachusetts
    • +7 more
    Aug 14, 2023

    Diffuse Glioma, Malignant Glioma Trial in Rochester (Biospecimen Collection, Computed Tomography, Eflornithine)

    Not yet recruiting
    • Diffuse Glioma
    • Malignant Glioma
    • Biospecimen Collection
    • +6 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Feb 6, 2023

    Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Cadonilimab combined Anlotinib
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Aug 6, 2023

    Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma Trial in Worldwide (INCB086550)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • +4 more
    • Burgas, Bulgaria
    • +19 more
    Oct 20, 2022

    Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

    Active, not recruiting
    • Advanced Malignant Solid Neoplasm
    • +9 more
    • New Brunswick, New Jersey
      Rutgers Cancer Institute of New Jersey
    Jan 25, 2023

    Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

    Recruiting
    • Ovarian Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Jul 13, 2022

      Healthy Participant Trial in Changchun (GST-HG171/Ritonavir, Itraconazole)

      Completed
      • Healthy Participant
      • Changchun, Jilin, China
        The first hospital of Jilin University
      Oct 11, 2023